The Wegovy formulation explained: injection, tablet and what's actually changed

You've been told Wegovy is an injection, then a friend mentions a tablet, here's what's actually going on

Until early 2026, Wegovy meant one thing in the UK: a pre-filled injection pen, self-administered once a week into the abdomen, thigh or upper arm. That is still the most widely recognised formulation. Each pen contains four weekly doses of semaglutide, a GLP-1 receptor agonist that works by mimicking a gut hormone involved in appetite regulation and gastric emptying. The treatment starts at a low dose to let the body adjust and is stepped up gradually by the prescriber, reaching 2.4mg weekly at the standard maintenance level, with a newer 7.2mg option now also approved for adults with a BMI of 30 or above.

On 11 June 2026 the MHRA approved a second formulation: a once-daily tablet. This made the UK the first European country to license an oral GLP-1 medicine specifically for weight management. The tablets contain the same active ingredient but are made quite differently, and that difference is worth understanding before assuming one formulation is simply interchangeable with the other. The full Wegovy overview covers the broader picture; this page focuses on what separates the two forms.

What the Wegovy tablet formulation actually contains, and why it needs a special coating

Semaglutide is a protein-based molecule. Swallow it in plain form and stomach acid would break it down before it reaches the bloodstream in any meaningful quantity. The oral Wegovy tablet solves this with a co-formulation approach: semaglutide is combined with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, known as SNAC, an absorption enhancer that temporarily raises the local pH at the stomach lining and allows semaglutide to pass through. It's an elegant bit of pharmaceutical chemistry, you can read more about the semaglutide molecule itself if the science interests you.

The practical consequence is a strict set of instructions around how the tablet is taken. It must be swallowed first thing in the morning on an empty stomach with a small amount of plain water (up to around 120ml). You then wait at least 30 minutes before eating, drinking anything else or taking other oral medicines. Missing that window, or taking the tablet with coffee, meaningfully reduces absorption. The injection carries no such timing constraint, it can be taken at any point in the week regardless of meals.

Storage is another difference worth knowing. The injection pen needs refrigerating at 2–8°C (the exact room-temperature window is in the Patient Information Leaflet and your prescriber will advise). The tablet stores at room temperature, which makes it considerably more travel-friendly. The Wegovy medication page covers practical handling in more detail.

Trial results: what the evidence shows for each formulation

The injection's evidence base is extensive. The STEP 1 trial, published in the New England Journal of Medicine, found an average body-weight reduction of around 15% over 68 weeks at 2.4mg weekly in adults with obesity who did not have type 2 diabetes, alongside lifestyle changes. That is the figure most people have heard cited for Wegovy.

The tablet's evidence comes from the OASIS 4 phase-3 trial: 307 adults with obesity or overweight plus at least one weight-related condition, without diabetes, over 64 weeks. Average weight loss was around 13.6% compared with roughly 2.4% on placebo, regardless of how closely participants stuck to the regimen. Among those who were fully adherent to treatment, the figure rose to around 17%. One important framing point: that higher number reflects full adherence, not the trial average, the two are not interchangeable when comparing formulations.

For context on how either formulation fits the broader landscape of medical weight loss, NICE and the MHRA set out the licensed eligibility criteria; the injection is covered by NICE TA875, while the tablet, being newly approved, awaits a formal NICE appraisal before NHS commissioning could begin. Private prescription is currently the only route to the tablet.

Which formulation might suit which person, and how that decision is made

Neither formulation is objectively better for every person. The injection has a longer evidence record, is established in clinical practice and is available through some NHS pathways (though waiting lists are often long). The tablet removes the element of self-injection entirely, which matters to some people a great deal, and its room-temperature storage suits busy or frequently travelling lives. The morning routine it requires is either straightforward or genuinely disruptive, depending on a person's schedule.

That question (injection or tablet) is exactly the kind of thing a prescriber works through with you. At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber on the same day, not by an automated system. They consider your medical history, any other medicines you take (the tablet's interaction with other morning medications matters here), and what you've told us about your lifestyle. If you'd like to see who leads that clinical oversight, our clinical team page has the details.

One thing worth knowing if you've been on the injection and are curious about the tablet: the MHRA has noted that patients stabilised on the 2.4mg weekly injection may be able to move directly to the 25mg tablet dose, rather than restarting from the beginning, subject to clinical assessment. That is a conversation for your prescriber, not a decision to make unilaterally. The Wegovy prescribing information page has more on how dose transitions work. For a straightforward look at how to obtain Wegovy through a legitimate UK pharmacy, that page explains the prescription process and what to check before ordering anywhere online. The NICE appraisal of semaglutide for weight management is also worth reading if you want to understand how the NHS framework for this medicine was built.

When your pen or tablet pack arrives from a registered pharmacy, it will come in plain, unbranded packaging via DPD, with tracking so you know exactly when it'll land. That detail matters if you're arranging to be home, or keeping things private.

If you'd like to check your eligibility and have a consultation reviewed the same day, the next step is a free consultation with our prescribers.